Harnessing Chronomodulation to Enhance Osteogenesis
NCT03911336 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL
Last updated 2022-06-21
Summary
Chronotherapy is an emerging field in biomedicine that leverages on fine-tuning the timing of drug delivery to obtain a therapeutic effect. Dr. Tamimi and his team have successfully harnessed chronotherapy using NSAIDs to enhance bone healing in a murine fracture model. Unpublished findings revealed that mice receiving carprofen for 3 days post-fracture exclusively during activity hours exhibited superior bone healing outcomes in comparison to specimens that received the same drug during resting hours.
This is a 3-arm RCT aimed at evaluating the effect of different chronotherapeutic NSAID regimens on intraoral bone healing in humans using an extraction socket healing model in the context of an early implant placement protocol.
The primary aim is to elucidate whether there are differences in osteogenesis and in the characteristics of the newly formed bone between patients following different post-operative NSAID chronotherapeutic protocols. Secondary endpoints of interest include assessment of alveolar bone and soft tissue dimensional changes between pre- and post-extraction, implant insertion torque, serum CRP levels, wound healing index and patient-reported discomfort at different time points.
If proven beneficial, the proposed chronotherapeutic approach could be readily implemented in clinical practice as a standalone therapy or as a valuable complement to existing standard-of-care protocols, due to its simplicity, safety and cost-effectiveness.
Conditions
- Tooth Loss
Interventions
- DRUG
-
Group A - test:Tooth extraction and intake of NSAID and a non-NSAID
Tooth extraction and intake of an NSAID (i.e. Ketoprofen ER 50 mg) at 8 AM and a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
- DRUG
-
Group B - Control 1: tooth extraction and intake of NSAID and a non-NSAID
Tooth extraction and intake of an NSAID (i.e. Ketoprofen ER 50 mg) at 8 PM and a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 8 AM and 2 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
- DRUG
-
Group C - Control 2: tooth extraction and intake of a Non-Nsaid
Tooth extraction and intake of a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 8AM, 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
Sponsors & Collaborators
-
University of Iowa
lead OTHER
Principal Investigators
-
Satheesh Elangovan, BDS DSc DMSc · University of Iowa
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2023-01-01
- Primary Completion
- 2023-01-01
- Completion
- 2023-01-01
More Related Trials
-
In Vivo Inhibition Profile of CYP2C9 by Pineapple Juice
NCT01649492 ·Status: UNKNOWN ·Phase: PHASE4
-
Non-steroidal Anti-inflammatory Affect on Kidneys in Endurance Distances
NCT02272725 ·Status: COMPLETED ·Phase: PHASE3
-
Actual Use Trial of Naproxen Sodium
NCT01427803 ·Status: COMPLETED ·Phase: PHASE3
-
Celebrex for Pain Relief After Oral Surgery
NCT00006299 ·Status: COMPLETED ·Phase: PHASE2
-
Resveratrol Trial for Relief of Pain in Pseudoachondroplasia
NCT03866200 ·Status: TERMINATED ·Phase: PHASE2
-
Effectiveness of Theramine on Chronic Back Pain
NCT01468025 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Trial to Compare Safety and Effectiveness for Relieving Tenderness of 10% Naproxen Gel vs. a 2.32% Diclofenac Diethylamine Gel in the Treatment of Strains and Bruises of the Legs.
NCT05026320 ·Status: COMPLETED ·Phase: PHASE2
-
Influence of Genotype of CYP2C9 on Clinical Efficacy and Pharmacokinetics of Piroxicam After Lower Third Molar Surgery
NCT02450487 ·Status: COMPLETED ·Phase: PHASE4
-
Bioequivalence of Single Dose Extended Release Naproxen Sodium (660 mg) Tablet Versus Naproxen Sodium (220 mg) Tablet Three Times Daily
NCT02549469 ·Status: COMPLETED ·Phase: PHASE1
-
A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects Under Fed Conditions
NCT03424135 ·Status: COMPLETED ·Phase: PHASE1
-
Phase I Study to Evaluate Bioavailability of Naproxen as PN400 Compared to Naproxen as Naprosyn E
NCT00907400 ·Status: COMPLETED ·Phase: PHASE1
-
Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome
NCT02052908 ·Status: COMPLETED ·Phase: PHASE1
-
A Multiple-Dose Pharmacokinetics Study of Two Gefapixant (AF-219/MK-7264) Formulations
NCT02492776 ·Status: COMPLETED ·Phase: PHASE1
-
Naproxen Sodium Extended-Release Actual Use Study
NCT00751400 ·Status: COMPLETED ·Phase: PHASE3
-
Comparative Bioavailability of Dexketoprofen Trometamol Oral Solution vs Tablet Formulations
NCT02209454 ·Status: COMPLETED ·Phase: PHASE1
-
Study Evaluating the Gastrointestinal Safety of PLA-695 Compared to Placebo and Naproxen
NCT00366262 ·Status: COMPLETED ·Phase: PHASE1
-
PF-06372865 In Subjects With Chronic Low Back Pain
NCT02262754 ·Status: COMPLETED ·Phase: PHASE2
-
Contribution of UGT2B17 to the Pharmacokinetics of Diclofenac
NCT06053411 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Clinical Trial Comparing Intravenous and Oral Diclofenac and Pharmacokinetics
NCT03472339 ·Status: UNKNOWN ·Phase: PHASE4
-
Phase I Study on Multiple Oral Dosing of CG100649
NCT01154790 ·Status: COMPLETED ·Phase: PHASE1
-
Naproxen Pharmacogenetic Study (Project 1, Aim 2)
NCT04449471 ·Status: UNKNOWN ·Phase: PHASE4
-
Fast & Fed Pharmacokinetic (PK) Study
NCT00692016 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacogenetic and Pharmacokinetics of Naproxen and Associated Naproxen-esomeprazole
NCT03092193 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.
NCT00367211 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults
NCT04139824 ·Status: COMPLETED ·Phase: PHASE1